Astrocytoma is a tumor that begins in star-shaped brain cells called astrocytes and can occur in the brain or spinal cord. Its behavior ranges from slow-growing low-grade tumors to aggressive high-grade cancers.
A clinical trial combining laser interstitial thermal therapy with pembrolizumab immunotherapy showed nearly half of recurrent high-grade astrocytoma patients alive at 18 months, far exceeding typical survival. Separate research reveals steroids make glioblastoma cells vulnerable to dietary interventions targeting their altered metabolism.
Rhythm Pharmaceuticals announced expanded Phase 3 TRANSCEND trial data showing an 18.8% placebo-adjusted BMI reduction at 52 weeks for setmelanotide in acquired hypothalamic obesity, with FDA PDUFA goal date set for March 20, 2026.
A clinical trial combining laser interstitial thermal therapy with pembrolizumab shows nearly half of patients with recurrent high-grade astrocytoma alive at 18 months, compared to zero in the control group.
The FDA is set to announce decisions in March 2026 on several drug applications, including label expansions for approved therapies and new drug candidates, with some making repeat approval attempts.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07560865 |
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma |
RECRUITING | PHASE1 |
| NCT07439172 |
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07417761 |
Tuvusertib in Astrocytoma With ATRX Mutation |
RECRUITING | PHASE2 |
| NCT06989086 |
FearLess in NeuroOncology |
RECRUITING | NA |
| NCT06797661 |
Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions. |
RECRUITING | NA |
| NCT06620926 |
Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma |
COMPLETED | |
| NCT06614855 |
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06439420 |
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial |
COMPLETED | PHASE2 |
| NCT06344130 |
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma |
RECRUITING | PHASE1 |
| NCT06241391 |
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas |
NOT_YET_RECRUITING | NA |
